8-K: Kiniksa Pharmaceuticals Announces Phase 2b Trial for Abiprubart in Sjogrens Disease and Positive Rheumatoid Arthritis Data

Kiniksa Pharmaceuticals plans to initiate a Phase 2b trial of abiprubart in Sjogrens Disease and has released positive topline data from a Phase 2 rheumatoid arthritis trial, while also expecting to remain cash flow positive.

Summary

• Kiniksa Pharmaceuticals announced plans to begin a Phase 2b clinical trial for abiprubart in Sjogrens Disease in the second half of 2024.
• The Phase 2b trial will be a randomized, double-blind, placebo-controlled study involving approximately 201 patients, evaluating two different dosing regimens of abiprubart against a placebo over 24 weeks.
• The primary endpoint of the Sjogrens trial is the change from baseline in the EULAR Sjogrens Syndrome Disease Activity Index (ESSDAI) at Week 24.
• Topline data from Cohort 4 of the Phase 2 rheumatoid arthritis trial showed a statistically non-significant improvement in the Disease Activity Score of 28 Joints Using C-reactive Protein (DAS28-CRP) at Week 12, with a reduction of 0.58 points compared to placebo (p=0.109).
• A statistically significant reduction of approximately 40% in Rheumatoid Factor was observed in the Cohort 4 abiprubart group (p=0.0003).
• A post-hoc analysis of pooled data from Cohorts 3 and 4 showed a statistically significant improvement in DAS28-CRP at Week 12 in the abiprubart group compared to placebo (p=0.010).
• Kiniksa expects to remain cash flow positive on an annual basis within its current operating plan, which includes the advancement of abiprubart through Phase 3 development in Sjogrens Disease.
• The company's ARCALYST product generated $233.2 million in net product revenue for the full year 2023, representing approximately 90% annual growth compared to 2022.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with the planned Phase 2b trial and positive data, but the lack of statistical significance in the Cohort 4 rheumatoid arthritis data and the inherent risks of drug development temper the overall sentiment.

Positives

• The planned Phase 2b trial of abiprubart in Sjogrens Disease represents a significant step forward in addressing an unmet medical need.
• The rheumatoid arthritis data, particularly the reduction in Rheumatoid Factor and the pooled analysis, suggests abiprubart has potential efficacy in autoimmune diseases.
• The company's expectation to remain cash flow positive indicates financial stability and the ability to fund ongoing research and development.
• The strong revenue growth of ARCALYST demonstrates the commercial success of Kiniksa's existing product portfolio.
• Abiprubart has shown a good safety profile in the Phase 2 rheumatoid arthritis trial, with no dose-related adverse experiences observed.

Negatives

• The topline data from Cohort 4 of the rheumatoid arthritis trial did not achieve statistical significance for the primary endpoint (DAS28-CRP).
• The company is still in the early stages of development for abiprubart in Sjogrens Disease, with Phase 3 trials still to come.
• The company is reliant on the success of its clinical trials and regulatory approvals for future growth.

Risks

• There are risks associated with clinical trial delays, patient enrollment, and the potential for negative or inconclusive results.
• The company relies on third parties for manufacturing and conducting clinical trials, which could lead to supply chain issues or delays.
• Regulatory authorities may not accept filings or may delay or deny approval of product candidates.
• There is competition from other companies developing treatments for autoimmune diseases.
• Changes in the company's operating plan, business development strategy, or funding requirements could impact future performance.

Future Outlook

Kiniksa expects to remain cash flow positive on an annual basis within its current operating plan, which includes the advancement of abiprubart through Phase 3 development in Sjogrens Disease. The company also anticipates continued growth in ARCALYST sales.

Management Comments

• Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa, stated that they believe abiprubart has the potential to provide meaningful benefit to patients suffering from Sjogrens Disease.
• Sanj K. Patel also noted that the company continues to execute a strategic and disciplined capital allocation approach.
• John F. Paolini, MD, PhD, Chief Medical Officer of Kiniksa, stated that the Phase 2 data demonstrates that abiprubart is a potentially efficacious and well-tolerated therapeutic approach for multiple autoimmune diseases.
• John F. Paolini also expressed confidence that abiprubart is highly active based on the comparable magnitude of reduction in Rheumatoid Factor across different dosing schedules.

Industry Context

The announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing treatments for autoimmune diseases. The initiation of a Phase 2b trial for Sjogrens Disease and the positive rheumatoid arthritis data position Kiniksa as a potential player in this space. The company's focus on immune-modulating assets aligns with current trends in drug development.

Comparison to Industry Standards

• The DAS28-CRP results in the rheumatoid arthritis trial are comparable to other treatments in development, although the Cohort 4 results did not reach statistical significance.
• The reduction in Rheumatoid Factor is a positive indicator of abiprubart's biological activity, similar to other successful therapies targeting B-cell activity.
• The planned Phase 2b trial in Sjogrens Disease is a significant step, as there are currently no FDA-approved therapies for this condition, making it a high unmet need area.
• Kiniksa's ARCALYST is a unique product in the recurrent pericarditis space, with no direct competitors, which is reflected in its strong revenue growth.
• The company's financial performance, particularly the growth in ARCALYST revenue, is strong compared to other companies in the same stage of development.

Stakeholder Impact

• Shareholders may react positively to the planned Phase 2b trial and the positive data, potentially increasing the share price.
• Employees may be motivated by the company's progress and financial stability.
• Patients with Sjogrens Disease and rheumatoid arthritis may benefit from the development of new treatment options.
• Customers of ARCALYST will continue to have access to a treatment for recurrent pericarditis.
• Suppliers and creditors will likely view the company as a stable and reliable partner.

Next Steps

• Initiate the Phase 2b clinical trial of abiprubart in Sjogrens Disease in the second half of 2024.
• Continue the Phase 2 rheumatoid arthritis trial with follow-up to Week 24.
• Advance abiprubart through Phase 3 development in Sjogrens Disease.
• Continue to drive commercial growth of ARCALYST.

Key Dates

Keywords

abiprubart, Sjogrens Disease, rheumatoid arthritis, clinical trial, Phase 2b, ARCALYST, autoimmune, CD40, monoclonal antibody, cash flow positive